

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 February 2024 (15.02.2024)



(10) International Publication Number
WO 2024/033626 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) A61K 47/26 (2006.01)
A61K 9/12 (2006.01) A61P 11/08 (2006.01)
A61K 9/00 (2006.01) A61K 45/06 (2006.01)
A61K 47/02 (2006.01)

(21) International Application Number:

PCT/GB2023/052084

(22) International Filing Date:

07 August 2023 (07.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/370,694	08 August 2022 (08.08.2022)	US
63/370,696	08 August 2022 (08.08.2022)	US
63/370,699	08 August 2022 (08.08.2022)	US
63/502,977	18 May 2023 (18.05.2023)	US

(71) Applicant: **VERONA PHARMA PLC** [GB/GB]; One Central Square, Cardiff CF10 1FS (GB).

(72) Inventors: **RHEAULT, Tara Renae**; 212 Council Gap Ct, Cary, North Carolina 27513 (US). **RICKARD, Kathleen**; 111 Burlington Mill Court, Durham, North Carolina 27703 (US). **BENGTTSSON, Thomas**; Valdemars väg 112, 22474 Lund (SE).

(74) Agent: **J A KEMP LLP**; 80 Turnmill Street, London Greater London EC1M 5QU (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ENSIFENTRINE (RPL-554) FOR DECREASING THE FREQUENCY AND/OR SEVERITY OF COPD EXACERBATIONS




FIGURE 1

(57) Abstract: The present invention relates to a compound for use in a method for decreasing the frequency and/or severity of chronic obstructive pulmonary disease (COPD) exacerbations in a patient suffering from COPD, wherein the compound is ensifentrine or a pharmaceutically acceptable salt thereof. The present invention also relates to a compound for use in a method for treating chronic obstructive pulmonary disease (COPD) in a patient, wherein: the compound is ensifentrine or a pharmaceutically acceptable salt thereof; and the patient is susceptible to COPD exacerbations.